Get the Daily Brief
Latest Biotech News
Myriad maps MRD rollout: five tissue‑informed tests and AI prostate assay planned
Myriad Genetics detailed a strategic product roadmap at JP Morgan, saying it will launch five tissue‑informed minimal residual disease (MRD) tests over the next two years targeting breast, renal,...
Precede Biosciences raises $84M to scale liquid biopsy platform for pharma
Precede Biosciences closed an $83.5–$84 million financing to expand its liquid biopsy platform focused on transcriptome‑level cancer profiling. The company said it will scale capacity to support...
Asimov licenses LV Edge: single‑plasmid lentiviral packaging for CDMOs
Asimov Therapeutics and AGC Biologics struck a licensing and manufacturing agreement to commercialize Asimov’s LV Edge Packaging cell line at AGC’s Milan cell & gene center. The system embeds...
Charles River acquires PathoQuest and primate supplier: bolstering QC and supply
Charles River Laboratories agreed to buy the remaining 79% of PathoQuest and the assets of K.F. (Cambodia), strengthening its NGS‑based biologics QC capabilities and securing nonhuman primate...
Novo Nordisk Foundation bankrolls European biotech incubator: 5.5bn DKK through 2035
The Novo Nordisk Foundation committed 5.5 billion Danish kroner (about $857 million) to extend funding for the BioInnovation Institute from 2026 through 2035. The pledge will expand the...
Illumina launches Billion Cell Atlas — pharma partners sign on for AI training
Illumina unveiled the Billion Cell Atlas, a genome‑wide genetic perturbation dataset designed to accelerate AI‑driven drug discovery and target validation. The resource, built from genetic...
FDA removes suicide warning from GLP‑1 obesity drugs — labeling updated
The U.S. Food and Drug Administration asked manufacturers to remove language about suicidal ideation and behavior from the warnings and precautions sections of several GLP‑1 obesity drug labels...
FDA clears Zycubo — first therapy for Menkes disease wins approval
The U.S. Food and Drug Administration approved Zycubo (copper histidinate, CUTX‑101) as the first treatment for Menkes disease, a rare pediatric disorder of copper absorption. The approval...
MRD market heats up: Myriad lays out multi‑cancer roadmap — Natera upgrades Signatera
Two liquid‑biopsy leaders sketched aggressive roadmaps for minimal residual disease (MRD) testing at JPM. Myriad told investors it will roll out tissue‑informed MRD assays across five tumor types...
Precede Biosciences raises $83.5M to scale liquid biopsy for drug development
Precede Biosciences closed an $83.5 million financing package (Series B plus a $20 million credit facility) to expand its liquid‑biopsy transcriptional platform for oncology. The Boston‑based...
Proxima (ex‑VantAI) nets $80M seed — AI for proximity‑modulating medicines
Proxima, the Roivant‑backed drug‑discovery firm formerly known as VantAI, raised an $80 million seed round to build AI platforms for designing proximity‑based therapeutics that modulate protein...
Caldera launches with China‑sourced IBD bispecific and Series A funding
Caldera Therapeutics formally launched with combined Series A and A‑1 financings totaling $112.5 million to develop an IBD candidate licensed from China’s Qyuns Therapeutics. The Cambridge, Mass....
CRISPR clinic countdown: Scribe readies first human trial — Cas3 shows therapeutic promise
Scribe Therapeutics announced plans to start the first human test of a CRISPR‑based cholesterol‑lowering therapy this summer, marking a near‑term clinical debut for a company built on engineered...
AbbVie strikes MFN pricing deal with White House — pledges industrial investments
AbbVie agreed to the Trump administration’s most‑favored‑nation (MFN) pricing framework and announced commitments to expand U.S. production capacity, pledging multibillion‑dollar investments. The...
Illumina launches billion‑cell atlas: AI gets a genome‑scale training set
Illumina announced the Billion Cell Atlas, a planned dataset of one billion genome‑wide genetic perturbations designed to train large AI models for drug discovery and target validation. The...
FDA asks industry to drop suicide warnings from GLP‑1 labels — regulators revise post‑market risk language
The U.S. Food and Drug Administration requested that manufacturers of GLP‑1 obesity drugs remove warnings about suicidal ideation and behavior from product labeling after a post‑market evaluation...
FDA clears Zycubo: first approved treatment for Menkes disease
The U.S. Food and Drug Administration approved Zycubo (copper histidinate, CUTX‑101) as the first therapy for Menkes disease, granting a rare pediatric disease priority review voucher to the...
AbbVie inks PD‑1/VEGF deal and signs MFN pact: global strategy widens
AbbVie agreed to an exclusive outside‑China licensing deal for RemeGen’s PD‑1/VEGF bispecific RC148, structuring $650 million upfront and up to $4.95 billion in milestones plus tiered royalties....
NVIDIA and Lilly pledge $1B AI lab: co‑innovation to speed drug discovery
NVIDIA and Eli Lilly announced a five‑year, $1 billion collaboration to create a Co‑Innovation AI Lab focused on accelerating AI applications in drug discovery and development. The partnership...
Proxima raises $80M — Roivant spinout rebrands and targets proximity‑modulating drugs
Proxima (formerly VantAI), a Roivant‑affiliated drug discovery firm, closed an $80 million seed round to fund AI‑driven discovery of proximity‑modulating therapeutics across cancer and immunology....